Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00313391 · ClinicalTrials.gov registry record · Phase 4
Risperdal Consta and Health Care Utilization in Patients With Schizophrenia
A Phase 4 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00313391: Completed Phase 4 study, sponsored by Emory University.
NCT00313391 is a Phase 4 study that has completed, run by Emory University. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00313391, a Phase 4 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous utilization costs under standard oral treatment of any atypical antipsychotic. We hypothesize that higher Risperdal Consta acquisition costs can be offset by reduction in total medical utilization costs, such as hospitalizations, ER visits, unscheduled outpatient visits or incarcerations due to worsening of psychotic symptoms.
Interventions
- DRUG Risperdal Consta
Trial Details
| Field | Value |
|---|---|
| Start Date | 2005-12 |
| Phase | Phase 4 |
What the finished NCT00313391 record still lists
NCT00313391 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Risperdal Consta is the first listed.
NCT00313391 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00313391 about?
NCT00313391 is a clinical study titled "Risperdal Consta and Health Care Utilization in Patients With Schizophrenia". The purpose of this study is to determine if Risperdal Consta will affect the healthcare utilization costs in chronically ill schizophrenic patients with multiple admissions to the psychiatric hospital compared to the previous utilization costs under standard oral treatment of any atypical antipsych...
What is the current status of trial NCT00313391?
This trial is currently completed. It is a Phase 4 study. The study started on 2005-12.
What interventions are being tested in trial NCT00313391?
The interventions under investigation include: Risperdal Consta (DRUG).
Who is sponsoring clinical trial NCT00313391?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia